Literature DB >> 3913775

Toxicity of low dose methotrexate in rheumatoid arthritis.

M E Weinblatt.   

Abstract

The efficacy and acceptability of low dose weekly methotrexate therapy in rheumatoid arthritis was reviewed in 587 patients in open and randomized trials. Gastrointestinal toxicity was reported most frequently. Bone marrow suppression, stomatitis, alopecia, headaches, and fever also occurred. A review of these adverse reactions, as well as of the effects of this drug on the reproductive, renal, and pulmonary systems, is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3913775

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  31 in total

1.  Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin.

Authors:  D J Chatterjee; W Y Li; R T Koda
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

2.  Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up.

Authors:  A A Drosos; D Psychos; A P Andonopoulos; S Stefanaki-Nikou; E B Tsianos; H M Moutsopoulos
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

Review 4.  Treatment of rheumatoid arthritis: state of the art 2009.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

5.  Isolated thrombocytopenia associated with low dose methotrexate therapy.

Authors:  G Lapadula; C De Bari; C A Acquista; F Dell'Accio; M Covelli; F Iannone
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

Review 6.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 7.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.

Authors:  Byung-Ryul Choi; Myung-Ju Ahn; Woong Soo Lee; Tae-Hwan Kim; Sang-Cheol Bae; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2004-08-25       Impact factor: 2.631

9.  Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial.

Authors:  Jeffrey A Sparks; Paul F Dellaripa; Robert J Glynn; Nina P Paynter; Chang Xu; Paul M Ridker; Daniel H Solomon
Journal:  Arthritis Rheumatol       Date:  2020-10-07       Impact factor: 10.995

10.  Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.

Authors:  Jeffrey A Sparks; Medha Barbhaiya; Elizabeth W Karlson; Susan Y Ritter; Soumya Raychaudhuri; Cassandra C Corrigan; Fengxin Lu; Jacob Selhub; Daniel I Chasman; Nina P Paynter; Paul M Ridker; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2017-02-10       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.